Disclosure of interest: nothing to disclose Poster Session II - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.02 - ACUTE MANAGEMENT - Thrombolysis or thrombectomy P649 - ESOC25-2457 FUTILITY OF ENDOVASCULAR TREATMENT IN ISCHEMIC STROKE DUE TO TERMINAL INTERNAL CAROTID ARTERY OCCLUSION: A MULTICENTER STUDY Carmen Ramos 1 , Elena Lopez-Cancio 2 , Laura Llull Estrany 3 , Mar Castellanos 4 , Saima Bashir 5 , Fernando Ostos Moliz 6 , Antonio Cruz Culebras 7 , Pablo Iriarte Uribe-Echeverra 1 , Maria Castaon 2 , Antonio Doncel-Moriano 3 , Alexia Roel Garcia 4 , Mikel Terceo 5 , Patrica Calleja 6 , Natalia Mena Garca 7 , Alejandro Rodriguez 4 , Emma Caada 1 , Santiago Trillo Senin *1 1 Hospital Universitario de La Princesa, Madrid, Spain, 2 Hospital Universitario Central de Asturias, Oviedo, Spain, 3 Hospital Universitario Clinic de Barcelona, Barcelona, Spain, 4 Complejo hospitalario Universitario de A Corua, A Corua, Spain, 5 Hospital Universitario Josep Trueta, Girona, Spain, 6 Hospital Universitario 12 de Octubre, Madrid, Spain, 7 Hospital Universitario Ramn y Cajal, Madrid, Spain Background and Aims: Ischemic stroke due to terminal internal carotid artery occlusion (TICA) is a sever condition, with poor functional outcomes often occurring after endovascular treatment (EVT)
At Perfect B, we utilize advanced GLP-1 therapies, including Semaglutide and Tirzepatide, to help you achieve sustainable Weight Loss without the constant battle of willpower
For those interested in optimizing energy without sacrificing muscle mass, combining a mild metabolic enhancer like 5-amino-1mq with MOTS-c can further amplify natural mitochondrial pathways, avoiding the dramatic appetite suppression associated with GLP-1 therapy
[PubMed: 20462641] 4
However, the high production costs, low permeability, insufficient clinical trials, and lack of comparison with standard medicines hinder the commercialization of most peptides
